Concourse Financial Group Securities, Inc. Vor Biopharma Inc. Transaction History

Concourse Financial Group Securities, Inc.

$0
Q1 2025

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

100.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share
Q1 2025 May 14, 2025	BUY	$0.72 - $1.74 $0 - $0
Q4 2024 Feb 13, 2025	BUY	$0.64 - $1.27 $0 - $0
Q3 2024 Oct 10, 2024	BUY	$0.7 - $1.1 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$1.0 - $2.2 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$1.8 - $2.85 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$1.66 - $2.63 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$2.1 - $3.35 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$2.1 - $3.35 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$3.09 - $5.33 $0 - $0
Q1 2023 May 15, 2023	BUY	$4.68 - $6.96 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$3.77 - $7.43 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$3.9 - $5.52 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$3.89 - $6.44 $0 - $0
Q1 2022 May 09, 2022	BUY	$6.04 - $12.23 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$11.32 - $18.02 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$12.24 - $20.38 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$18.65 - $38.78 $0 - $0
Q1 2021 May 13, 2021	BUY	$30.96 - $54.08 $0 - $0

Others Institutions Holding VOR

# of Institutions

Shares Held

54.1M

Call Options Held

Put Options Held

Ra Capital Management, L.P. Boston, MA

39.6M
Shares

$7.93 Million
0.59% of portfolio
5 Am Venture Management, LLC San Francisco, CA

6.36M
Shares

$1.27 Million
3.17% of portfolio
Vanguard Group Inc Valley Forge, PA

1.94M
Shares

$388,044
0.0% of portfolio
Johnson & Johnson New Brunswick, NJ

1.07M
Shares

$214,931
0.26% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

701K
Shares

$140,286
0.0% of portfolio

View Full List

About Vor Biopharma Inc.

Ticker VOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,056,300
Market Cap $7.61M
Description
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AM...

More about VOR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account